Caregiver conversations
Expert advice on framing discussions with caregivers around risk/benefit of treatment and the need for echocardiogram (ECHO) monitoring when prescribing FINTEPLA.
With Professor Catherine (Kate) Riney
FINTEPLA cardiac
safety profile
Caregiver
hesitation
Echocardiogram
(ECHO) strategies
PBS Information: Authority required for Dravet syndrome. Not listed for Lennox-Gastaut syndrome. Refer to pbs.gov.au for further information.
Please review Product Information before prescribing FINTEPLA®. The full Product Information is available here.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
WARNING: VALVULAR HEART DISEASE AND PULMONARY ARTERIAL HYPERTENSION
See Section 4.4 Special Warnings and Precautions for further detail.
There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in Fintepla®), and valvular heart disease and pulmonary arterial hypertension. Echocardiogram assessments are required before, during and after treatment with Fintepla®. Fintepla® is only available through a controlled access program.
AU-FA-2500178. January 2026